Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). The secondary objectives of Part 1 of the study are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy [DC] or comfort measures only [CMO], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI.
The objectives of Part 2 of the study are to evaluate long-term disability following LHI, to evaluate long-term outcome measures of clinical function, quality of life, and healthcare utilization, and to assess the safety of BIIB093 in subjects with LHI during the follow-up period.
Inclusion Criteria:
A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory.
A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters cubed (cm^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions.
Screening National Institutes of Health Stroke Scale (NIHSS) >=10.
At the time of randomization, and in the Investigator's judgement, it must be feasible for study drug treatment infusion to be initiated no later than 10 hours after time of symptom onset, if known, or the time last known normal.
For participants who receive thrombectomy, inclusion into the study must be based on post-thrombectomy MRI-DWI.
Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Kansas City, Kansas 66160, United States
New York, New York 10032, United States
Providence, Rhode Island 02905, United States
Wuhan, Hubei 430030, China
Xi’an, Shanxi 710004, China
Chongqing, Sichuan 400042, China
Copenhagen NV, Copenhagen City 2400, Denmark
Bad Neustadt Saale, Bavaria 97616, Germany
Kistarcsa, Budapest 2143, Hungary
Brescia, 25123, Italy
Milan, 20162, Italy
Toyota-shi, Aichi-ken 471-8513, Japan
Hachinohe-shi, Aomori 039-1104, Japan
Kisarazu-shi, Chiba 292-8535, Japan
Onga-gun, Fukuoka 807-0051, Japan
Yukuhashi-shi, Fukuoka 824-0026, Japan
Koriyama-shi, Fukushima 963-8052, Japan
Fukuyama-shi, Hiroshima 720-0825, Japan
Asahikawa-shi, Hokkaido 070 8530, Japan
Akashi-shi, Hyōgo 674-0064, Japan
Kobe, Hyōgo 650-0047, Japan
Tsuchiura-shi, Ibaraki 300-0028, Japan
Kawasaki-shi, Kanagawa 216-8511, Japan
Kurashiki-shi, Okayama-ken 710-8602, Japan
Hidaka-shi, Saitama 350 1298, Japan
Fuchu-shi, Tokyo-To 183-8524, Japan
Mitaka-shi, Tokyo-To 181-8611, Japan
Tanabe-shi, Wakayama 646 8558, Japan
Ube-shi, Yamaguchi 755-8505, Japan
Santa Maria da Feira, Aveiro District 4520-211, Portugal
Matosinhos Municipality, Porto District 4454-509, Portugal
Coimbra, 3000-075, Portugal
Kazan', Respublka Tatarstan 420061, Russia
Saint Petersburg, Sankt-Peterburg 192242, Russia
Daegu, Gyeongsangnam-do 41944, South Korea